Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, will present the company's first Tumor Paint product, BLZ-100, at SPIE Photonics West 2016 in San Francisco, 13-18 February.
BLZ-100 is the first Tumor Paint product candidate being developed for cancer surgery in multiple solid tumor types. BLZ-100 is a drug administered by IV injection that circulates within the body and "lights up" cancer cells. It consists of an optide, which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range.
Preclinical utility of BLZ-100 has been demonstrated in a wide range of cancer types, including brain, breast, prostate, lung, colorectal, skin, and sarcomas. BLZ-100 is currently in multiple Phase 1 clinical trials.